Td Asset Management Inc Avrobio, Inc. Transaction History

Td Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$12.79 - $17.1 $213,797 - $285,843	-16,716 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$10.08 - $27.21 $27,205 - $73,439	2,699 Added 19.26%	16,716 $260,000
Q4 2019 Feb 11, 2020	SELL	$13.05 - $21.88 $41,616 - $69,775	-3,189 Reduced 18.53%	14,017 $282,000
Q3 2019 Nov 07, 2019	BUY	$14.12 - $23.44 $38,152 - $63,334	2,702 Added 18.63%	17,206 $243,000
Q2 2019 Aug 01, 2019	SELL	$13.21 - $27.29 $7,926 - $16,374	-600 Reduced 3.97%	14,504 $236,000
Q1 2019 May 08, 2019	SELL	$12.46 - $22.05 $29,904 - $52,920	-2,400 Reduced 13.71%	15,104 $333,000
Q3 2018 Nov 01, 2018	BUY	$26.95 - $52.7 $266,805 - $521,730	9,900 Added 130.19%	17,504 $908,000
Q2 2018 Jul 31, 2018	BUY	$28.08 - $31.2 $213,520 - $237,244	7,604 New	7,604 $217,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.